乳腺导管原位癌影像学诊断、病理学升级及影像学技术进展

doi:10.3760/cma.j.cn371439-20231130-00026

国际肿瘤学杂志 ›› 2024, Vol. 51 ›› Issue (3): 166-169.doi: 10.3760/cma.j.cn371439-20231130-00026

乳腺导管原位癌影像学诊断、病理学升级及影像学技术进展

张丽丽¹, 谭茹², 房雪利¹, 杨宇¹, 桑铮¹, 李宝生¹()

¹山东第一医科大学附属肿瘤医院放疗科，济南 250117
²山东第一医科大学附属省立医院影像科，济南 250021

收稿日期:2023-11-30 修回日期:2023-12-26 出版日期:2024-03-08 发布日期:2024-04-10
通讯作者: 李宝生，Email： baoshli1963@163.com

Imaging diagnosis， pathological upgrade， and imaging technology progress of ductal carcinoma in situ of the breast

Zhang Lili¹, Tan Ru², Fang Xueli¹, Yang Yu¹, Sang Zheng¹, Li Baosheng¹()

¹Department of Radiation Oncology， Cancer Hospital Affiliated to Shandong First Medical University， Jinan 250117， China
²Department of Imaging， Shandong Provincial Hospital Affiliated to Shandong First Medical University， Jinan 250021， China

Received:2023-11-30 Revised:2023-12-26 Online:2024-03-08 Published:2024-04-10
Contact: Li Baosheng， Email： baoshli1963@163.com

摘要/Abstract

摘要：

乳腺导管原位癌（DCIS）X线最常见的表现为无症状钙化，MRI最常见的表现为非肿块性强化，超声主要表现为不规则的低回声富血供肿块，不伴后方特征。空芯针穿刺活检术是术前诊断DCIS的常用方式，由于穿刺针类型及取样大小的差异，病变存在一定程度的病理学升级。近年来，对于DCIS的诊断和治疗一直存在争议。随着乳腺疾病诊断技术的发展，数字乳腺断层合成摄影、人工智能和影像组学的进展均有望帮助管理DCIS和解决过度诊断等问题。

关键词: 癌, 导管内, 非浸润性, 影像学诊断, 病理学升级

Abstract:

Ductal carcinoma in situ of the breast （DCIS） most commonly manifests as asymptomatic calcifications at mammography. The most common manifestation of MRI is nonmass enhancement. The ultrasound mainly presents as a hypoechoic irregular hypervascular mass without posterior features. Core-needle biopsy is a commonly used method for preoperative diagnosis of DCIS. Due to differences in needle type and sample size， there is a certain degree of pathological upgrading of the lesion. In recent years， there has been controversy over the diagnosis and treatment of DCIS. With the development of breast disease diagnostic technology， advances in digital breast tomography， artificial intelligence， and radiomics are expected to help DCIS management and address issues such as overdiagnosis.

Key words: Carcinoma, intraductal, noninfiltrating, Imaging diagnosis, Pathology upgrade

张丽丽, 谭茹, 房雪利, 杨宇, 桑铮, 李宝生. 乳腺导管原位癌影像学诊断、病理学升级及影像学技术进展[J]. 国际肿瘤学杂志, 2024, 51(3): 166-169.

Zhang Lili, Tan Ru, Fang Xueli, Yang Yu, Sang Zheng, Li Baosheng. Imaging diagnosis， pathological upgrade， and imaging technology progress of ductal carcinoma in situ of the breast[J]. Journal of International Oncology, 2024, 51(3): 166-169.

参考文献 25

[1]	Wilson GM, Dinh P, Pathmanathan N, et al. Ductal carcinoma in situ: molecular changes accompanying disease progression[J]. J Mammary Gland Biol Neoplasia, 2022, 27(1): 101-131. DOI: 10.1007/s10911-022-09517-7.
[2]	Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(6): 524-541. DOI: 10.3322/caac.21754.
[3]	Salvatorelli L, Puzzo L, Vecchio GM, et al. Ductal carcinoma in situ of the breast: an update with emphasis on radiological and morphological features as predictive prognostic factors[J]. Cancers (Basel), 2020, 12(3): 609. DOI: 10.3390/cancers12030609.
[4]	Grimm LJ, Rahbar H, Abdelmalak M, et al. Ductal carcinoma in situ: state-of-the-art review[J]. Radiology, 2022, 302(2): 246-255. DOI: 10.1148/radiol.211839.
[5]	D'Orsi CJ. Imaging for the diagnosis and management of ductal carcinoma in situ[J]. J Natl Cancer Inst Monogr, 2010, 2010(41): 214-217. DOI: 10.1093/jncimonographs/lgq037.
[6]	Kim G, Mikhael PG, Oseni TO, et al. Ductal carcinoma in situ on digital mammography versus digital breast tomosynthesis: rates and predictors of pathologic upgrade[J]. Eur Radiol, 2020, 30(11): 6089-6098. DOI: 10.1007/s00330-020-07021-2.
[7]	Chou SS, Romanoff J, Lehman CD, et al. Preoperative breast MRI for newly diagnosed ductal carcinoma in situ: imaging features and performance in a multicenter setting (ECOG-ACRIN E4112 trial)[J]. Radiology, 2021, 301(1): 66-77. DOI: 10.1148/radiol.2021204743.
[8]	Bragg A, Candelaria R, Adrada B, et al. Imaging of noncalcified ductal carcinoma in situ[J]. J Clin Imaging Sci, 2021, 11: 34. DOI: 10.25259/JCIS_48_2021. pmid: 34221643
[9]	Shehata M, Grimm L, Ballantyne N, et al. Ductal carcinoma in situ: current concepts in biology, imaging, and treatment[J]. J Breast Imaging, 2019, 1(3): 166-176. DOI: 10.1093/jbi/wbz039. pmid: 31538141
[10]	Amornsiripanitch N, Lam DL, Rahbar H. Advances in breast MRI in the setting of ductal carcinoma in situ[J]. Semin Roentgenol, 2018, 53(4): 261-269. DOI: 10.1053/j.ro.2018.08.006. pmid: 30449344
[11]	Oda G, Nakagawa T, Ogawa A, et al. Predictors for upstaging of ductal carcinoma in situ (DCIS) to invasive carcinoma in non-mass-type DCIS[J]. Mol Clin Oncol, 2020, 13(1): 67-72. DOI: 10.3892/mco.2020.2036.
[12]	Greenwood HI, Wilmes LJ, Kelil T, et al. Role of breast MRI in the evaluation and detection of DCIS: opportunities and challenges[J]. J Magn Reson Imaging, 2020, 52(3): 697-709. DOI: 10.1002/jmri.26985. pmid: 31746088
[13]	van Seijen M, Lips EH, Thompson AM, et al. Ductal carcinoma in situ: to treat or not to treat, that is the question[J]. Br J Cancer, 2019, 121(4): 285-292. DOI: 10.1038/s41416-019-0478-6.
[14]	Schmitz RSJM, Wilthagen EA, van Duijnhoven F, et al. Prediction models and decision aids for women with ductal carcinoma in situ: a systematic literature review[J]. Cancers (Basel), 2022, 14(13): 3259. DOI: 10.3390/cancers14133259.
[15]	Moon HJ, Kim EK, Kim MJ, et al. Comparison of clinical and pathologic characteristics of ductal carcinoma in situ detected on mammography versus ultrasound only in asymptomatic patients[J]. Ultrasound Med Biol, 2019, 45(1): 68-77. DOI: 10.1016/j.ultrasmedbio.2018.09.003. pmid: 30322671
[16]	Brennan ME, Turner RM, Ciatto S, et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer[J]. Radiology, 2011, 260(1): 119-128. DOI: 10.1148/radiol.11102368. pmid: 21493791
[17]	Nicosia L, Bozzini AC, Penco S, et al. A model to predict upsta-ging to invasive carcinoma in patients preoperatively diagnosed with low-grade ductal carcinoma in situ of the breast[J]. Cancers (Basel), 2022, 14(2): 370. DOI: 10.3390/cancers14020370.
[18]	Chong A, Weinstein SP, McDonald ES, et al. Digital breast tomosynthesis: concepts and clinical practice[J]. Radiology, 2019, 292(1): 1-14. DOI: 10.1148/radiol.2019180760. pmid: 31084476
[19]	范文文, 欧阳汉, 周纯武, 等. 数字乳腺断层成像与磁共振成像对乳腺肿瘤的诊断价值[J]. 放射学实践, 2020, 35(3): 360-364. DOI: 10.13609/j.cnki.1000-0313.2020.03.020.
[20]	杨彩仙, 赵宏光, 刘慧, 等. 乳腺癌数字化X线三维断层摄影肿块边缘征象及其与病理学指标的相关性[J]. 肿瘤研究与临床, 2019, 31(1): 16-21. DOI: 10.3760/cma.j.issn.1006-9801.2019.01.004.
[21]	Park KW, Kim SW, Han H, et al. Ductal carcinoma in situ: a risk prediction model for the underestimation of invasive breast cancer[J]. NPJ Breast Cancer, 2022, 8(1): 8. DOI: 10.1038/s41523-021-00364-z. pmid: 35031626
[22]	Shi B, Grimm LJ, Mazurowski MA, et al. Prediction of occult invasive disease in ductal carcinoma in situ using deep learning features[J]. J Am Coll Radiol, 2018, 15(3 Pt B): 527-534. DOI: 10.1016/j.jacr.2017.11.036. pmid: 29398498
[23]	Zhu Z, Harowicz M, Zhang J, et al. Deep learning analysis of breast MRIs for prediction of occult invasive disease in ductal carcinoma in situ[J]. Comput Biol Med, 2019, 115: 103498. DOI: 10.1016/j.compbiomed.2019.103498.
[24]	Hou R, Grimm LJ, Mazurowski MA, et al. Prediction of upstaging in ductal carcinoma in situ based on mammographic radiomic features[J]. Radiology, 2022, 303(1): 54-62. DOI: 10.1148/radiol.210407.
[25]	Lee HJ, Park JH, Nguyen AT, et al. Prediction of the histologic upgrade of ductal carcinoma in situ using a combined radiomics and machine learning approach based on breast dynamic contrast-enhanced magnetic resonance imaging[J]. Front Oncol, 2022, 12: 1032809. DOI: 10.3389/fonc.2022.1032809.

乳腺导管原位癌影像学诊断、病理学升级及影像学技术进展

Imaging diagnosis， pathological upgrade， and imaging technology progress of ductal carcinoma in situ of the breast

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 15

编辑推荐

Metrics

本文评价

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[6]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[7]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[8]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[9]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[10]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[11]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[12]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[13]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[14]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[15]	钱晓涛, 石子宜, 胡格. Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.